When we divided the patients into CYP2D6 *10 T/T and non-*10 T/T, no significant difference in risks of adverse effects (liver dysfunction events, dyslipidemia events, and gynecological events) was found (p = 0.599, > 0.999 and 0.437). Here, CYP2D6 is linked to metabolic syndrome.